2H-Pyrazolo<4,3-c>chinolin | 233-44-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2H-Pyrazolo<4,3-c>chinolin
• 英文别名: 2H-pyrazolo[4,3-c]quinoline；1H-Pyrazolo[4,3-c]quinoline
• CAS: 233-44-3
• 化学式: C₁₀H₇N₃
• 分子量: 169.186
• InChiKey: ADEJACPCTOIQLO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2H-Pyrazolo<4,3-c>chinolin 在 碘 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以98 %的产率得到3-iodo-1H-pyrazolo[4,3-c]quinoline
  参考文献：
  名称：

  [EN] SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF
  [FR] 1H-PYRAZOLO[4,3-C]QUINOLÉINES SUBSTITUÉES, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION

  摘要：

  The present invention is generally directed to inhibitors of hematopoietic progenitor kinase 1 (HPK1) and FMS-like tyrosine kinase 3 (FLT3) gene, useful in the treatment of diseases and disorders modulated by said HPK1, and FLT3 having the Formula I:

  公开号：

  WO2023064133A1
• 作为产物：
  描述：

  4-氯-3-喹啉甲醛 在 一水合肼 作用下， 以96 %的产率得到2H-Pyrazolo<4,3-c>chinolin
  参考文献：
  名称：

  [EN] SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF
  [FR] 1H-PYRAZOLO[4,3-C]QUINOLÉINES SUBSTITUÉES, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION

  摘要：

  The present invention is generally directed to inhibitors of hematopoietic progenitor kinase 1 (HPK1) and FMS-like tyrosine kinase 3 (FLT3) gene, useful in the treatment of diseases and disorders modulated by said HPK1, and FLT3 having the Formula I:

  公开号：

  WO2023064133A1

文献信息

• [EN] PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF<br/>[FR] DÉRIVÉS DE PYRAZOLOQUINOLINONE, LEUR PRÉPARATION ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：SANOFI SA

  公开号：WO2013045400A1

  公开（公告）日：2013-04-04

  The invention relates to compounds corresponding to formula (I), in which R1, R2 and R3 are as defined in Claim 1, and also to the process for preparing them and to their therapeutic use.

  这项发明涉及与式（I）相对应的化合物，其中R1、R2和R3如权利要求1中所定义，并且还涉及制备它们的过程以及它们的治疗用途。
• Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase
  申请人：Konradi W. Andrei

  公开号：US20080021056A1

  公开（公告）日：2008-01-24

  The invention provides compounds of formula I: or pharmaceutically salts thereof where R 1 , R 2 , and the A, B, and C-rings are as defined herein. Compounds of formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's disease. The invention also encompasses pharmaceutical compositions comprising compounds or salts of formula I, methods of preparing the desired compounds, and methods of treating cognitive disorders, such as Alzheimer's disease, using the compounds or salts of formula I.

  该发明提供了公式I的化合物： 或其药用盐，其中R 1 ，R 2 和A、B和C环如本文所定义。公式I的化合物在治疗或预防认知障碍，如阿尔茨海默病方面是有用的。该发明还涵盖了包括公式I的化合物或盐的药物组合物，制备所需化合物的方法，以及使用公式I的化合物或盐治疗认知障碍，如阿尔茨海默病的方法。
• PYRAZOLOQUINOLINE DERIVATIVES
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US20130143907A1

  公开（公告）日：2013-06-06

  A compound and/or pharmacologically acceptable salt thereof represented by the formula (I) has PDE9 inhibitory action, so that the intracerebral cGMP concentration is anticipated to be elevated. The PDE9 inhibitory action and the increase in cGMP lead to the improvement of learning and memory behaviors, and the compound (I) has applicability as a therapeutic agent for cognitive dysfunctions in Alzheimer's disease. wherein R 1 is a hydrogen atom; R 2 is an aromatic ring group, etc.; R 3 is a hydrogen atom, etc; R 4 is a hydrogen atom; R 5 is an oxepanyl group, etc.; R 6 is a hydrogen atom.

  由以下化学式（I）表示的化合物和/或药理学上可接受的盐具有PDE9抑制作用，因此预期将提高脑内cGMP浓度。PDE9抑制作用和cGMP的增加导致学习和记忆行为的改善，化合物（I）具有作为治疗代理人用于阿尔茨海默病认知功能障碍的适用性。其中R1是氢原子；R2是芳香环基团等；R3是氢原子等；R4是氢原子；R5是氧杂环丙基团等；R6是氢原子。
• Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
  申请人：——

  公开号：US20030125361A1

  公开（公告）日：2003-07-03

  The present invention relates to substituted pyrazolyl derivatives, compositions comprising such, intermediates, methods of making substituted pyrazolyl derivatives, and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis.

  本发明涉及取代的吡唑基衍生物、包含这种衍生物的组合物、中间体、制备取代吡唑基衍生物的方法，以及治疗癌症、炎症和与炎症相关的疾病，如关节炎的方法。
• [EN] PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE<br/>[FR] DÉRIVÉS DE PYRAZOLO[4,3-C]QUINOLINE POUR L'INHIBITION DE Β-GLUCURONIDASE
  申请人：DCB-USA LLC

  公开号：WO2016191576A1

  公开（公告）日：2016-12-01

  The present invention provides novel pyrazolo[4,3-c]quinoline derivatives exhibiting specifically inhibition activity to microbiota β-glucuronidase, whereby providing potent activities to prevent chemotherapy-induced diarrhea (CID) of cancers. Therefore, the compounds of the present invention can be used as (1) chemotherapy-adjuvant to prevent chemotherapy-induced diarrhea (CID) and enhance chemotherapeutic efficiency of cancers; (2) health-food supplement to prevent the carcinogens induced colon carcinoma.

  本发明提供了一种新型的吡唑并[4,3-c]喹啉衍生物，其具有特异性抑制微生物群体β-葡萄糖醛酸酶的活性，从而提供了强大的活性，以预防癌症化疗引起的腹泻。因此，本发明的化合物可以用作(1)化疗辅助剂，以预防化疗引起的腹泻，并增强癌症的化疗效果；(2)健康食品补充剂，以预防致癌物质引起的结肠癌。